Clin2
NCT07688161Possibly a fitNot yet recruiting

Herbal granules for diarrhea-predominant IBS (cold-dampness type)

Diarrhea-predominant Irritable Bowel Syndrome

Part of Digestive system clinical trials.

This study tests whether a traditional Chinese herbal formula called Jingfang Granules can ease diarrhea and belly pain in people with irritable bowel syndrome (IBS-D). It is for those whose IBS symptoms fit a specific pattern in Chinese medicine (cold-dampness).

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
106 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You have been diagnosed with diarrhea-predominant IBS for at least 6 months and meet specific symptom criteria (Rome IV) in the last 3 months.
  • Your symptoms fit a traditional Chinese medicine pattern called 'cold-dampness disturbing spleen' (e.g., cold, bloating, loose stools).
  • You are between 18 and 65 years old.
  • You have not taken any IBS medications, antibiotics, steroids, probiotics, or herbal preparations for at least 1 week before starting the trial.
  • You do not have serious health conditions (heart, liver, kidney disease, diabetes, cancer, mental illness) or other digestive diseases.
  • You are not pregnant or breastfeeding, and have not had abdominal or anorectal surgery.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06737666Recruiting· Phase 1
Tong-Xie-Yao-Fang for Diarrhea-Predominant IBS

This trial tests an herbal formula called Tong-Xie-Yao-Fang for people with diarrhea-predominant irritable bowel syndrome (IBS-D). It aims to see if the treatment helps symptoms and how it works. Healthy volunteers are also needed for comparison.

Beijing, Beijing Municipality
NCT06753890Not yet recruiting· Phase 3
Changkang Granules for Diarrhea-Predominant IBS

This trial tests if Changkang Granules can reduce abdominal pain and diarrhea in people with irritable bowel syndrome (IBS) where the main symptom is loose stools. It is specifically for those whose condition fits a pattern in traditional Chinese medicine called 'Liver qi affecting the Spleen.'

Baoding
NCT07610434Not yet recruiting· Phase 3
Traditional Chinese Medicine for Diarrhea-Dominant IBS

This trial tests whether Changji'an Capsules, a traditional Chinese medicine, can reduce symptoms of IBS with diarrhea (abdominal pain, bloating, and loose stools). The trial is for people aged 18–65 who have been diagnosed with this condition and may not have responded well to other treatments.

Beijing, Dongcheng District
NCT07721012Not yet recruiting· Phase 2
Huanghou Zhixie Diwan for IBS with Diarrhea

This trial tests a traditional Chinese medicine pill for people with irritable bowel syndrome where diarrhea is the main symptom. It's for those who have at least moderate abdominal pain and frequent loose stools, and meet specific traditional Chinese medicine criteria.

Beijing
NCT07061184Not yet recruiting· Phase 4
Testing Fengliao Changweikang for IBS with diarrhea

This trial is testing a Chinese herbal formula called Fengliao Changweikang for people with diarrhea-predominant irritable bowel syndrome (IBS-D). It uses an N-of-1 design, meaning each person serves as their own control to see if the treatment works for them.

Beijing, Beijing Municipality
NCT07715760Not yet recruiting
Hewei Anchang formula for overlapping stomach and bowel symptoms

This trial tests a traditional Chinese medicine formula (Hewei Anchang) for people who have both functional dyspepsia (upset stomach without clear cause) and diarrhea-predominant irritable bowel syndrome. It aims to see if the formula improves overlapping symptoms and how it works.

Beijing, Beijing Municipality

Hear when a new Diarrhea-predominant Irritable Bowel Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.